🔴 Novartis is trading 4.03% down in after-hours trading — no identified catalyst

Novartis is trading at $155.99, a -4.03% move, after the November 6 regular-session close; no verified catalyst explains the after-hours decline.

• Reuters reported two tumor cases with evidence linking them to Novartis’s Zolgensma gene therapy; Novartis said it had received nine tumor reports overall.
• The report appeared during the trading day, and afternoon coverage said shares were still up, so it does not establish a reason for the later decline.
• The supplied broad-market context does not show a matching market-wide drop.